* Cimzia® (certolizumab pegol) packaging wins international "Red
    Dot" design award
  * Patient-centric approach drove innovation in Cimzia® packaging
    components


Brussels (Belgium), August 12th, 2009 - UCB announced today that the
newly designed Cimzia® packaging was honoured with a "Red Dot
Communication Design" award, given by a respected international jury
for the largest and most renowned global design competition, the "Red
Dot Award".

The Red Dot Awards recognize the best in product design,
communication design, and design concepts. This year their
Communication Design competition received over 6000 entries from 42
countries. Winners of this coveted award are evaluated according to
criteria such as degree of innovation, functionality and the formal
quality.

"For Cimzia® in rheumatoid arthritis (RA), UCB developed premium
packaging components that shift the paradigm of pharmaceutical
packaging by designing for the consumer first. I am proud of this
patient-centric approach and the fact that people living with
rheumatoid arthritis worked directly with the design teams to develop
the Cimzia® packaging," said Roch Doliveux, CEO of  UCB.

UCB partnered with OXO Good Grips®, a company dedicated to Universal
(or "inclusive") Design, to develop their new Cimzia® syringe and
packaging components. As OXO®'s long-time design partner, Smart
Design led the team in developing all the elements of the new Cimzia®
packaging components (the syringe itself, the packaging and the
accompanying guides).

Davin Stowell, CEO and founder of Smart Design, explains the
approach. "The design team immersed themselves in the world of people
who live with RA in order to really understand their experience with
limited dexterity. We developed a syringe and packaging components
designed specifically for RA patients. We aimed to make patients feel
more in control during the process of self-injection, more empowered,
instead of reminding them of their illness."

Cimzia®'s friendly packaging not only aims to promote compliance but
also aims to provide a positive, caring user experience. A curved
front panel allows fingers to slide under and lift it open. Following
three easy steps, the design leads users through a thoughtful and
straightforward process. The tray accommodates a wide range of
patients' dexterity limitations when removing the syringe. The
information hierarchy is clear and concise with a personal,
conversational tone that is human and respectful.

As part of the packaging components, a "step-by-step" guide extracts
key information from the full Patient Information Leaflet. The guide
follows the same design as the box, and includes simple photography
that aims to communicate the features of the syringe at a quick
glance, highlighting the ergonomic design and OXO® brand
collaboration.

UCB, OXO® and Smart Design will receive the award at a gala awards
dinner in Essen, Germany on December 9, 2009.


Further information
Nancy Nackaerts, External Communications, UCB
T +32.2.559.9264, nancy.nackaerts@ucb.com

Mercedes Coats, Marketing Communications Manager SMART DESIGN
T +1415 355 6205, Mercedes.Coats@SmartDesignWorldwide.com

Gretchen Holt, Corporate Communications Manager OXO
 T +1212 242 3333, gholt@oxo.com


Notes to Editors

About Cimzia®
Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor).
Cimzia® has a high affinity for human TNF-alpha, selectively
neutralizing the pathophysiological effects of TNF-alpha. Over the
past decade, TNF-alpha has emerged as a major target of basic
research and clinical investigation. This cytokine plays a key role
in mediating pathological inflammation, and excess TNF-alpha
production has been directly implicated in a wide variety of
diseases. The U.S. Food and Drug Administration (FDA) has approved
Cimzia® for reducing signs and symptoms of Crohn's disease and
maintaining clinical response in adult patients with moderately to
severely active disease who have had an inadequate response to
conventional therapy and for the treatment of adults with moderately
to severely active rheumatoid arthritis. Cimzia® was approved in
Switzerland for induction of a clinical response and for the
maintenance of a clinical response and a remission in patients with
active Crohn's disease who have not responded adequately to
conventional treatment in September 2007. UCB is also developing
Cimzia® in other autoimmune disease indications. Cimzia® is a
registered trademark of UCB S.A.

OXO® and GOOD GRIPS® are trademarks of Helen of Troy Limited (NASDAQ
HELE) and are used under license.

Important safety information
The most common adverse reactions belonged to the system organ
classes Infections and infestations, reported in 15.5% of patients on
Cimzia and 7.6% of patients on placebo, and General disorders and
administration site conditions, reported in 10.0% of patients on
Cimzia and 9.7% of patients on placebo. The most serious adverse
reactions were serious infections (including tuberculosis and
histoplasmosis), malignancies (including lymphoma) and heart failure.
A pooled analysis of the safety data show there was a low incidence
of injection site pain (1.5%) and low level of discontinuations due
to adverse events.

Cimzia® is contraindicated in patients with active tuberculosis or
other severe infections such as sepsis, abscesses and opportunistic
infections and in patients with moderate to severe heart failure.
Before initiation of Cimzia®, evaluate patients for both active or
inactive (latent) tuberculosis infection. Monitor patients for the
development of signs and symptoms of infection during and after
treatment with Cimzia®. If an infection develops, monitor carefully,
and stop Cimzia® if infection becomes serious.

Use of TNF blockers, including Cimzia®, may increase the risk of
reactivation of hepatitis B virus (HBV) in patients who are chronic
carriers of this virus, of new onset or exacerbation of clinical
symptoms and/or radiographic evidence of demyelinating disease, in
the formation of autoantibodies and uncommonly in the development of
a lupus-like syndrome or of severe hypersensitivity reactions
following Cimzia administration. If a patient develops any of these
adverse reactions, Cimzia® should be discontinued and appropriate
therapy instituted.

Adverse reactions of the hematologic system, including medically
significant cytopenia, have been infrequently reported with Cimzia®.
Advise all patients to seek immediate medical attention if they
develop signs and symptoms suggestive of blood dyscrasias or
infection (e.g., persistent fever, bruising, bleeding, pallor) while
on Cimzia®. Consider discontinuation of Cimzia® therapy in patients
with confirmed significant haematological abnormalities.

The use of Cimzia® in combination with biological DMARDS such as
anakinra, abatacept and rituximab is not recommended due to a
potential increased risk of serious infections. As no data are
available, Cimzia® should not be administered concurrently with live
vaccines or attenuated vaccines.

Please see full prescribing information before prescribing.

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing approximately 10 000
people in over 40 countries, UCB generated revenue of EUR 3.6 billion
in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

About OXO
Founded in 1990 on the concept of Universal Design, OXO's mission is
to create consumer household products that ease the tasks of everyday
life for the widest range of users possible. Since the original 15
items were introduced, the OXO collection has grown to more than 800
strong covering areas for cooking, cleaning, gardening, storing,
organizing and lighting. Today OXO Good Grips products are sold in 54
countries and are included in the permanent collections of numerous
museums. The company has won more than 100 design and business awards
worldwide. OXO is very frequently used as a case study on how a
well-executed Universal Design philosophy can be a successful
business strategy. OXO is owned by Helen of Troy Limited, a leading
designer, producer and global marketer of brand-name personal care
and household consumer products.

About Smart Design
Smart Design has been turning insight and innovation into successful
consumer experiences for 30 years. As OXO's partner in designing the
original line of OXO Good Grips products, Smart Design was
instrumental in bringing the principles of Universal Design to the
mass market. Their strategic approach brings together experts in
product, brand, and interaction design, business factors,
engineering, and design research to ensure that its solutions connect
with people. Smart Design's consistent results are delivered by a
130-member international staff - working in teams across offices in
New York, San Francisco, and Barcelona. www.smartdesignworldwide.com

About Red Dot Design Award
With more than 11 000 submissions from 61 countries, the
international "red dot design award" is the largest and most renowned
design competition in the world. It is divided into the "Red Dot
Award: Product Design", the "Red Dot Award: Communication Design" and
the "Red Dot Award: Design Concept." The award-winning products are
put before an international public in the red dot design museum. Each
year an international jury reviews and evaluates the submitted
products according to criteria such as degree of innovation,
functionality and the formal quality. The group of jurors is made up
of renowned designers and design experts from all over the world.

Forward-looking statements
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.

This press release contains links to external websites that are out
of UCB editorial control.


For the pdf-version of this press release, please click on the link
below:

hugin.info/133973/R/1334025/316476.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.